跳至主要内容
临床试验/NCT00459888
NCT00459888已完成4 期

CLIMB Prospective Multicenter Registry Evaluating the Use of the PolarCath Peripheral Dilatation System (Boston Scientific) in the Treatment of Infrapopliteal Lesions in Patients With Critical Limb Ischemia (Rutherford 4 and 5).

Flanders Medical Research Program8 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2007年5月1日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
100
试验地点
8
主要终点
Clinical patency

研究概览

简要总结

In 5 Belgian hospitals, the data of 100 CLI-patients receiving the cryoplasty technique to treat their infrapopliteal arterial lesions will be collected. The treatment occurs strictly according the "Instructions For Use" of the CE-approved device (PolarCath Peripheral Dilatation System, Boston Scientific) and only data are collected that have been made available conform the Standard the Standards of Care for these patients.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Symptomatic CLI male or female patients with at least 1 atherosclerotic diseased infrapopliteal artery. If patients present with more than 1 diseased vessel, only the vessel with the best distal run-off providing the foot with blood, will be assessed following treatment with the PolarCath Peripheral Dilatation System (Boston Scientific) and analysed for registry purposes.
  • Patients will be considered eligible for inclusion into the registry if satisfying the product DFU specifications.

排除标准

  • 未提供

结局指标

主要结局

Clinical patency

时间窗: 12 months

次要结局

  • Technical success(procedure)
  • angiographic outcomes for the subgroup of patients in which made available.(12 months)
  • Primary patency rate(12 months)
  • Limb-salvage rate(12 months)
  • Serious adverse events(12 months)
  • Clinical success (improvement of Rutherford classification)(12 months)
  • Health Economics assessment(12 months)

研究者

申办方类型
Network

研究点 (8)

Loading locations...

相似试验